Latest Calcipotriol Stories
MISSISSAUGA, ON, Feb. 12, 2015 /PRNewswire/ - Cipher Pharmaceuticals Inc.
PARSIPPANY, New Jersey, January 6, 2015 /PRNewswire/ -- LEO Pharma announces it has submitted a New Drug Application (NDA) for calcipotriene and betamethasone dipropionate
PARSIPPANY, N.J., Jan. 19 /PRNewswire-USNewswire/ -- Denmark-based LEO Pharma, a global leader in dermatology and critical care, today announced its official launch in the U.S. Headquartered in Parsippany, New Jersey, LEO Pharma U.S.
- 52-Week Data Supports Long-term Use of Vectical(TM) Ointment, Satisfying an Unmet Need Among Psoriasis Patients - FORT WORTH, Texas, April 30 /PRNewswire/ -- Galderma Laboratories, L.P.
- Significant efficacy differences widen 6 weeks after treatment stops - SAN FRANCISCO, March 10 /PRNewswire/ -- A nonprescription topical solution made with a new formulation of liquor carbonis distillate (LCD), known as PSORENT(R), is significantly more effective than prescription-strength calcipotriol cream in improving and controlling the symptoms of plaque psoriasis, according to research findings presented at the American Academy of Dermatology's 2009 Annual Meeting.
Incyte Corporation (Nasdaq:INCY) reported positive results from two 28-day Phase IIa clinical trials of topical INCB18424, a selective janus-associated kinase (JAK) inhibitor, in patients with mild to moderate psoriasis.
PRINCETON, N.J., July 31 /PRNewswire/ -- NeoStrata today announced findings from an ongoing 12-week study that demonstrates benefits of a novel topically applied LCD (coal tar) solution (Psorent(TM)) versus calcipotriol cream (Dovonex(R)) in treatment of moderate plaque psoriasis.
- Growing in low tufty patches.